Division of Cardiovascular Medicine, Stanford University School of Medicine, Falk CVRC, Stanford Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA.
Med Clin North Am. 2011 Sep;95(5):875-92. doi: 10.1016/j.mcna.2011.06.002.
There seems to be general agreement that the prevalence of obesity is increasing in the United States and that we are in the midst of an obesity epidemic. The disease-related implications of this epidemic have received an enormous amount of publicity in the popular media, but public awareness of the untoward effects of excess weight has not led to an effective approach to dealing with the dilemma. The gravity of the problem is accentuated in light of the report that only approximately 50% of physicians polled provided weight loss counseling. Given the importance of excess adiposity as increasing the risk of CVD, 2DM, and hypertension and the combination of an increase in the prevalence of overweight/obesity and a health care system unprepared to deal with this situation, it is essential that considerable thought be given as to how to best address this dilemma. In this context, it must be emphasized that CVD, 2DM, and hypertension are characterized by resistance to insulin-mediated glucose disposal and that insulin resistance and the compensatory hyperinsulinemia associated with insulin resistance have been shown to be independent predictors of all three clinical syndromes. It has also been apparent for many years that overweight/obese individuals tend to be insulin resistant and become more insulin sensitive with weight loss.25 In light of these observations, it seems reasonable to suggest that insulin resistance is the link between overweight/obesity and the adverse clinical syndromes related to excess adiposity. The evidence summarized in this review shows that the more overweight an individual, the more likely he or she is insulin resistant and at increased risk to develop all the abnormalities associated with this defect in insulin action. Not all overweight/obese individuals are insulin resistant, however, any more than all insulin resistant individuals are overweight/obese. More important, there is compelling evidence that CVD risk factors are present to a significantly greater degree in the subset of overweight/obese individuals that is also insulin resistant. Not surprisingly,we have also demonstrated that an improvement in CVD risk factors with weight loss occurs to a significantly greater degree in those overweight/obese individuals who are also insulin resistant at baseline. In view of the ineffectiveness of current clinical approaches to weight loss, it seems necessary to recognize that not all overweight/obese individuals are at equal risk to develop CVD and that it is clinically useful to identify those at highest risk. The simplest way to achieve this task seems to be focusing on the CVD risk factors that are highly associated with insulin resistance/hyperinsulinemia. If this is done, then intense efforts at weight control can be brought to bear on those who not only need it the most but also have the most to gain by losing weight.
似乎大家普遍认为,美国的肥胖症患病率正在上升,我们正处于肥胖症流行之中。这种流行对疾病的影响已经在大众媒体上引起了极大的关注,但公众对体重过重的不良影响的认识并没有导致有效解决这一困境的方法。鉴于超重作为增加心血管疾病 (CVD)、2 型糖尿病 (2DM) 和高血压风险的重要因素,以及超重/肥胖患病率的增加和医疗保健系统对此情况准备不足的情况,认真考虑如何最好地解决这一困境至关重要。在这种情况下,必须强调的是,CVD、2DM 和高血压的特点是对胰岛素介导的葡萄糖处置产生抵抗,并且已经证明胰岛素抵抗和与胰岛素抵抗相关的代偿性高胰岛素血症是这三种临床综合征的独立预测因素。多年来,人们已经明显认识到超重/肥胖个体往往存在胰岛素抵抗,并且随着体重减轻而变得更加敏感。25 鉴于这些观察结果,似乎可以合理地提出,胰岛素抵抗是超重/肥胖与与过多脂肪相关的不良临床综合征之间的联系。本综述中总结的证据表明,个体越超重,他或她越有可能出现胰岛素抵抗,并增加发生与胰岛素作用缺陷相关的所有异常的风险。然而,并非所有超重/肥胖的个体都存在胰岛素抵抗,就像并非所有胰岛素抵抗的个体都超重/肥胖一样。更重要的是,有令人信服的证据表明,在超重/肥胖个体中,存在更显著的心血管疾病危险因素,这些个体也存在胰岛素抵抗。毫不奇怪,我们还表明,与基线时也存在胰岛素抵抗的超重/肥胖个体相比,体重减轻对心血管疾病危险因素的改善程度要大得多。鉴于目前临床减肥方法的无效性,似乎有必要认识到,并非所有超重/肥胖的个体都面临同等的心血管疾病风险,并且识别出风险最高的个体在临床上是有用的。实现这一任务的最简单方法似乎是关注与胰岛素抵抗/高胰岛素血症高度相关的心血管疾病危险因素。如果这样做,那么就可以对那些不仅最需要而且减肥获益最大的人进行强烈的体重控制努力。